- Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk. Barron’s
- Pfizer scraps daily weight loss pill after liver injury in one patient CNBC
- Pfizer Abandons Obesity Pill After Liver Injury in Setback Bloomberg.com
- Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out MarketWatch
- Viking Therapeutics Rockets On Pfizer’s High-Profile Obesity Setback Investor’s Business Daily
Powered by WPeMatico